**Title:**
Evaluation of the efficacy and safety of an immunomodulator as a treatment for canine soft tissue sarcoma

**Investigator:**
Corey Saba, DVM, DACVIM (Oncology faculty)

If interested, please have your primary veterinarian request additional information through the UGA Oncology service by calling the small animal referral coordinator at 706-542-5362.

**Study description:**
Soft tissue sarcomas (STS) are one of the most common skin tumors in dogs. Although complete surgical removal is the current treatment of choice, this is not always possible due to the location, size, and/or number of tumors. Therefore, an effective treatment that can induce regression of STS with minimal side effects is desirable. The purpose of this study is to evaluate the efficacy and safety of an immunomodulator as an alternative to surgery in dogs with STS.

The following conditions must be met:

**Inclusion criteria:**
1. Dogs must be otherwise healthy.
2. They must have measurable, histopathologically-confirmed, cutaneous STS to participate.
3. Dogs must reside with their owners within driving distance of UGA.
4. Owners must sign a consent form including consent for necropsy if unexpected death occurs during the study.

**Dogs having received previous immunotherapy are not eligible for this trial.**

**Specific questions about potential cases should be directed to the study investigator.**

Dogs will undergo preliminary staging tests including initial consultation, physical examination, tumor measurements, complete blood count (CBC), serum biochemical profile, urinalysis, 3-view chest x-rays, and tumor biopsy to determine trial eligibility. Additional staging tests (e.g. imaging) may be recommended at the discretion of the attending clinician. Once accepted into the study, the intent will be to administer the immunomodulator once weekly for 3 weeks, followed by physical examination and tumor measurements 1- and 2- weeks after treatment completion, then every 6 weeks thereafter. Dogs in this study are required to come to UGA for all scheduled visits, and owners will be expected to complete daily quality of life assessments for their dogs during the immunomodulator treatment phase.

Owners are responsible for the costs of all staging tests. Once enrolled, the costs of office visits and immunomodulator injections will be covered by the study. The immunomodulator will also be provided as part of the study.

**Duration of study:**
The study is currently OPEN. Enrollment opportunities are limited and will terminate when the target enrollment is filled.
Potential benefits to veterinary medicine:
We expect this trial will provide valuable information about the efficacy and safety of the immunomodulator in dogs with STS.